Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

Y. Summers · SciRah

Researcher profile · Semantic Scholar

Y. Summers

Share profile

Y. Summers — researcher profile on SciRah

h-index: 31
Works: 191
Citations: 9,032

Most-cited papers

Lung adenocarcinoma promotion by air pollutants
William Hill, Emilia L. Lim, C. Weeden, Claudia Lee +322 more
2023Nature710 citations Open access
Semantic Scholar
Tracking early lung cancer metastatic dissemination in TRACERx using ctDNA
C. Abbosh, A. Frankell, T. Harrison, Judit Kisistók +302 more
2023Nature355 citations Open access
Semantic Scholar
The evolution of lung cancer and impact of subclonal selection in TRACERx
A. Frankell, M. Dietzen, Maise Al Bakir, Emilia L. Lim +76 more
2023Nature275 citations Open access
Semantic Scholar
The evolution of non-small cell lung cancer metastases in TRACERx
Maise Al Bakir, Ariana Huebner, Carlos Martínez-Ruiz, Kristiana Grigoriadis +282 more
2023Nature217 citations Open access
Semantic Scholar
RETRACTED ARTICLE: Antibodies against endogenous retroviruses promote lung cancer immunotherapy
K. Ng, J. Boumelha, K. Enfield, J. Almagro +327 more
2023Nature202 citations Open access
Semantic Scholar
Pulmonary venous circulating tumour cell dissemination before tumour resection and disease relapse
Francesca Chemi, D. Rothwell, N. Mcgranahan, S. Gulati +30 more
2019Nature Medicine183 citations Open access
Semantic Scholar
Pembrolizumab in patients with non-small-cell lung cancer of performance status 2 (PePS2): a single arm, phase 2 trial.
G. Middleton, K. Brock, J. Savage, R. Mant +10 more
2020The Lancet Respiratory Medicine150 citations Open access
Semantic Scholar
The National Lung Matrix Trial of personalized therapy in lung cancer
G. Middleton, Peter Fletcher, S. Popat, J. Savage +23 more
2020Nature120 citations Open access
Semantic Scholar
Ultrasensitive ctDNA detection for preoperative disease stratification in early-stage lung adenocarcinoma
J. Black, G. Bartha, C. Abbott, S. Boyle +276 more
2025Nature Medicine102 citations Open access
Semantic Scholar
Extended pleurectomy decortication and chemotherapy versus chemotherapy alone for pleural mesothelioma (MARS 2): a phase 3 randomised controlled trial
E. Lim, D. Waller, K. Lau, J. Steele +49 more
2024The Lancet Respiratory Medicine102 citations Open access
Semantic Scholar
Representative Sequencing: Unbiased Sampling of Solid Tumor Tissue.
K. Litchfield, S. Stanislaw, L. Spain, L. Gallegos +176 more
2020Cell Reports70 citations Open access
Semantic Scholar
NEPTUNE: Phase III Study of First-Line Durvalumab Plus Tremelimumab in Patients With Metastatic NSCLC.
G. de Castro, N. Rizvi, P. Schmid, K. Syrigos +18 more
2022Journal of Thoracic Oncology64 citations Open access
Semantic Scholar
Mixed responses to targeted therapy driven by chromosomal instability through p53 dysfunction and genome doubling
S. Hobor, Maise Al Bakir, C. Hiley, M. Skrzypski +291 more
2024Nature Communications49 citations Open access
Semantic Scholar
Defining the road map to a UK national lung cancer screening programme.
E. O'Dowd, Richard W. Lee, A. Akram, E. Bartlett +24 more
2023The Lancet Oncology40 citations Open access
Semantic Scholar
Large cell neuroendocrine lung carcinoma: consensus statement from The British Thoracic Oncology Group and the Association of Pulmonary Pathologists
C. Lindsay, E. Shaw, D. Moore, D. Rassl +23 more
2021British Journal of Cancer33 citations Open access
Semantic Scholar
A phase I study of nintedanib combined with cisplatin/gemcitabine as first-line therapy for advanced squamous non-small cell lung cancer (LUME-Lung 3).
M. Forster, A. Hackshaw, T. De Pas, M. Cobo +9 more
2018Lung Cancer26 citations Open access
Semantic Scholar
Correlation between treatment effects on response rate and progression-free survival and overall survival in trials of targeted therapies in molecularly enriched populations
B. Solomon, H. Loong, Y. Summers, Z. Thomas +6 more
2022ESMO Open18 citations Open access
Semantic Scholar
DNA methylation cooperates with genomic alterations during non-small cell lung cancer evolution
F. Gimeno-Valiente, Carla Castignani, Elizabeth Larose Cadieux, N. Mensah +264 more
2025Nature Genetics15 citations Open access
Semantic Scholar
Experience With the Routine Use of Electronic Patient-Reported Outcome Measures for Patients With Lung Cancer
C. Crockett, J. Price, Mai Pham, D. Abdulwahid +23 more
2023JCO Clinical Cancer Informatics15 citations
Semantic Scholar
Unique correlation between GTF2I mutation and spindle cell morphology in thymomas (type A and AB thymomas)
Kirsty Wells, Angela Lamrca, G. Papaxoinis, A. Wallace +3 more
2022Journal of Clinical Pathology15 citations
Semantic Scholar
External control cohorts for the single-arm LIBRETTO-001 trial of selpercatinib in RET+ non-small-cell lung cancer
C. Rolfo, L. M. Hess, M. Jen, P. Peterson +7 more
2022ESMO Open14 citations Open access
Semantic Scholar
Developing and testing a web‐based intervention to encourage early help‐seeking in people with symptoms associated with lung cancer
Julia Mueller, Alan Davies, Caroline Jay, Simon Harper +4 more
2018British Journal of Health Psychology14 citations Open access
Semantic Scholar
Evolutionary characterization of lung cancer metastasis
S. Hessey, A. Bunkum, Ariana Huebner, Kerstin Haase +59 more
2026Nature13 citations Open access
Semantic Scholar
Consolidation thoracic radiotherapy after chemoimmunotherapy in ES-SCLC: A multicentric retrospective analysis.
F. Monaca, I. Gomez-Randulfe, G. Walls, Ornella Cantale +17 more
2025European Journal of Cancer11 citations Open access
Semantic Scholar
Real-World Data on Pembrolizumab for Pretreated Non-Small-Cell Lung Cancer: Clinical Outcome and Relevance of the Lung Immune Prognostic Index
A. Ortega-Franco, C. Hodgson, H. Raja, M. Carter +7 more
2022Targeted oncology11 citations
Semantic Scholar
First-line osimertinib compared to earlier generation TKIs in advanced EGFR-mutant NSCLC: A real-world survival analysis.
I. Gomez-Randulfe, Lauren A. Scanlon, Mathew Carter, Laura Moliner +7 more
2025Lung Cancer10 citations
Semantic Scholar
Correlation between irAEs and survival outcomes in patients with ES-SCLC treated with first-line chemoimmunotherapy.
F. Monaca, I. Gomez-Randulfe, A. Parreira, Vito Longo +15 more
2025European Journal of Cancer9 citations Open access
Semantic Scholar
A phase II trial of mTORC1/2 inhibition in STK11 deficient non small cell lung cancer
Gary Middleton, H. Robbins, Peter Fletcher, J. Savage +19 more
2025npj Precision Oncology9 citations Open access
Semantic Scholar
PL03.10 MARS 2: A Multicentre Randomised Trial Comparing (Extended) Pleurectomy Decortication versus No Radical Surgery for Mesothelioma
E. Lim, D. Waller, K. Lau, J. Steele +49 more
2023Journal of Thoracic Oncology9 citations
Semantic Scholar
Efficacy and safety of nivolumab plus ipilimumab for patients with pre-treated type B3 thymoma and thymic carcinoma: Results from the EORTC-ETOP NIVOTHYM phase II trial.
N. Girard, B. Besse, M. Duruisseaux, L. Greillier +15 more
2025Journal of Clinical Oncology7 citations
Semantic Scholar
1269P EMPOWER-lung 4: Phase II, randomized, open-label high dose or standard dose cemiplimab alone/plus ipilimumab in the second-line treatment of advanced non-small cell lung cancer (NSCLC)
B. Shim, S. Lee, J. de Castro Carpeño, C. Chiu +9 more
20207 citations Open access
Semantic Scholar
Loss of IDH1 and IDH2 mutations during the evolution of metastatic chondrosarcoma
W. Cross, Iben Lyskjær, Christopher Davies, A. Bunkum +242 more
2025Genome Biology6 citations Open access
Semantic Scholar
A global phase 2/3, randomized, open-label trial of BNT327/PM8002 in combination with chemotherapy (chemo) in first-line (1L) non-small cell lung cancer (NSCLC).
S. Peters, Stephen V. Liu, Vinod Ganju, S. Kosmider +15 more
2025Journal of Clinical Oncology4 citations Open access
Semantic Scholar
Abstract LB260: Potential prognostic/predictive biomarkers for sacituzumab govitecan in EVOKE-01
M. Garassino, Peiwen Kuo, N. Reinmuth, N. Girard +8 more
2025Cancer Research4 citations
Semantic Scholar
An open-label, multicenter phase I/IIa study evaluating the safety and clinical activity of clonal neoantigen reactive T cells in patients with advanced non-small cell lung cancer (CHIRON).
M. Jamal-Hanjani, A. Greystoke, F. Thistlethwaite, Y. Summers +11 more
2021Journal of Clinical Oncology4 citations
Semantic Scholar
Patient-reported outcomes (PROs) in the randomized, phase III IMpower110 study of atezolizumab (atezo) vs chemotherapy in 1L metastatic NSCLC.
F. de Marinis, G. Giaccone, R. Herbst, C. Oprean +14 more
20204 citations
Semantic Scholar
Publisher Correction: Pulmonary venous circulating tumor cell dissemination before tumor resection and disease relapse
Francesca Chemi, D. Rothwell, N. Mcgranahan, S. Gulati +31 more
2020Nature Medicine4 citations Open access
Semantic Scholar
Author Correction: The evolution of lung cancer and impact of subclonal selection in TRACERx
A. Frankell, M. Dietzen, Maise Al Bakir, Emilia L. Lim +76 more
2024Nature3 citations Open access
Semantic Scholar
Service Evaluation of MyChristie-MyHealth, an Electronic Patient-Reported Outcome Measure Integrated Into Clinical Cancer Care
Lee A Shipman, James Price, D. Abdulwahid, N. Bayman +18 more
2024JCO Clinical Cancer Informatics3 citations
Semantic Scholar
Publisher Correction: The National Lung Matrix Trial of personalized therapy in lung cancer
G. Middleton, Peter Fletcher, S. Popat, J. Savage +23 more
2020Nature3 citations Open access
Semantic Scholar
Afatinib, an irreversible ErbB family blocker for the treatment of epidermal growth factor receptor mutation-positive non-small cell lung cancer
Y. Summers, D. Graham
2019European Journal of Oncology Pharmacy3 citations Open access
Semantic Scholar
1864P Real-world comparative effectiveness of sotorasib versus docetaxel monotherapy in second-line and beyond for advanced or metastatic non-small cell lung cancer (NSCLC): A national database analysis from England
Y. Summers, N. Karim, K. Arnold, T. Akram +5 more
2025Annals of Oncology2 citations Open access
Semantic Scholar
OA08.06 Sacituzumab Govitecan vs Docetaxel in Patients with mNSCLC Non-responsive to Last Anti-PD-(L)1-containing Regimen: EVOKE-01
M. Garassino, O. Juan-Vidal, E. Felip, N. Girard +14 more
2024Journal of Thoracic Oncology2 citations Open access
Semantic Scholar
82P The role of circadian rhythms in NSCLC immunotherapy efficacy: A focus on first dose timing
M. I. Gómez-Randulfe Rodríguez, M. Pearce, F. Gomes, C. Lindsay +6 more
2023Immuno-Oncology and Technology2 citations Open access
Semantic Scholar
Correlation between overall response rate and progression-free survival/overall survival in comparative trials involving targeted therapies in molecularly enriched populations.
B. Solomon, H. Loong, Y. Summers, Z. Thomas +6 more
20202 citations
Semantic Scholar
Pneumocystis jirovecii pneumonia (PJP) prophylaxis in lung cancer patients receiving radical radiotherapy (RT) ± chemotherapy (CTRT): audit of the first UK departmental guideline
A. Beech, C. Faivre-Finn, N. Bayman, F. Blackhall +15 more
2020Lung Cancer2 citations
Semantic Scholar
Real-world comparative effectiveness of sotorasib versus docetaxel monotherapy in second line and beyond for advanced or metastatic non-small cell lung cancer: A national database analysis from England.
N. Karim, Kellyn F. Arnold, Y. Summers, T. Akram +6 more
2026Lung Cancer1 citations Open access
Semantic Scholar
Evaluation of Biomarkers for Sacituzumab Govitecan in Metastatic Non–Small Cell Lung Cancer: Insights From the EVOKE-01 Study
E. Felip, Peiwen Kuo, Pilar Garrido, C. Chouaid +10 more
2026Cancer Research Communications1 citations Open access
Semantic Scholar
Longer follow-up for survival and safety from the EVOKE-01 trial of sacituzumab govitecan (SG) vs docetaxel in patients (pts) with metastatic non-small cell lung cancer (mNSCLC).
N. Reinmuth, M. Garassino, Ó. Juan-Vidal, N. Girard +13 more
2025Journal of Clinical Oncology1 citations Open access
Semantic Scholar
Exploratory ctDNA analyses for the EVOKE-1 study in metastatic non-small cell lung cancer (mNSCLC).
E. Felip, Peiwen Kuo, Pilar Garrido, C. Chouaid +8 more
2025Journal of Clinical Oncology1 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

A. Hackshaw×15
Invite
A. Hackshaw — researcher profile on SciRah
S. Veeriah×14
Invite
S. Veeriah — researcher profile on SciRah
N. Mcgranahan×14
Invite
N. Mcgranahan — researcher profile on SciRah
C. Hiley×14
Invite
C. Hiley — researcher profile on SciRah

×13

Invite

Maise Al Bakir — researcher profile on SciRah

Invite

S. Ward — researcher profile on SciRah

Invite

T. Watkins — researcher profile on SciRah

C. Naceur-Lombardelli×12

Invite

C. Naceur-Lombardelli — researcher profile on SciRah

A. Toncheva×12

Invite

A. Toncheva — researcher profile on SciRah

Ariana Huebner×12

Invite

Ariana Huebner — researcher profile on SciRah

Invite

D. Biswas — researcher profile on SciRah

Invite

M. Falzon — researcher profile on SciRah